AbbVie Stock Forecast for 2023 - 2025 - 2030
Updated on 09/26/2023
AbbVie Stock Forecast and Price Target
AbbVie's stock is projected to advance by 6.64% from the previous closing price if it reaches the average target of $165.00 by the year's end, as sixteen reputable analysts recently projected. This potential upside is calculated on a high-end estimate of $200.00 and a low-end estimate of $120.00. Even if you are not interested in ABBV stock, it is still imperative to be aware of its competitors.
6.64% Upside
AbbVie Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, AbbVie's Price has seen a drop from $96.73 to $72.39 – a 25.17% decrease. For next year, the 23 analysts predict Fair Value of $129.95, which would mean an increase of 79.52%. Over the next eight years, the pros' prediction is Fair Valueof $154.94, which would mean a eight-year growth forecast of 114.05%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
14
|
$552.32 | Buy/Sell | $333.19 | -27.58% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$160.26 | Buy/Sell | $179.95 | 12.63% |
| AZN Stock Forecast | AstraZeneca PLC | Buy |
8
|
£11.14k | Buy/Sell | £153.20 | -98.60% |
| OR Stock Forecast | L'Oréal | Outperform |
10
|
358.60€ | Buy/Sell | 366.71€ | 3.88% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$97.47 | Buy/Sell | $124.05 | 28.24% |
AbbVie Revenue Forecast for 2023 - 2025 - 2030
In the last three years, AbbVie's Revenue has grown, increasing from $33.27B to $58.05B – an increase of 74.51%. According to 19 major analysts, AbbVie's Revenue will fall by 3.66% in the next year, reaching $55.93B. Over the next eight years, the pros' prediction is Revenueof $63.93B, which would mean a eight-year growth forecast of 10.12%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$59.16 | Buy/Sell | $80.99 | 40.30% |
| ABI Stock Forecast | Anheuser-Busch InBev SA/NV | Outperform |
5
|
57.44€ | Buy/Sell | 68.16€ | 16.68% |
| AMGN Stock Forecast | Amgen Inc | Hold |
7
|
$266.86 | Buy/Sell | $268.00 | 4.17% |
.jpg)
AbbVie Dividend per Share Forecast for 2023 - 2025 - 2030
AbbVie's Dividend per Share has increased by 34.85% In the last three years, going from $4.39 to $5.92. In the next year, analysts expect Dividend per Share to reach $6.00 – an increase of 1.35%. For the next eight years, the forecast is for Dividend per Share to grow by 3.55%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$74.85 | Buy/Sell | $87.30 | 17.57% |
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$266.77 | Buy/Sell | $300.43 | 3.09% |
| GSK Stock Forecast | GSK | Outperform |
16
|
£1.53k | Buy/Sell | £16.95 | -98.95% |
AbbVie Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last three years, AbbVie's Free Cash Flow has grown by 175117338.25%, from $12.77B to $22366.00T. In the following year, 9 experts forecast that AbbVie's Free Cash Flow will decrease by 100.00%, to $23.54B. In 2030, professionals predict that AbbVie's Free Cash Flow will decrease by 100.00%, to $27.84B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MMM Stock Forecast | 3M Co | Hold |
16
|
$94.79 | Buy/Sell | $147.79 | 26.07% |
| BAYN Stock Forecast | Bayer | Outperform |
7
|
46.32€ | Buy/Sell | 74.54€ | 63.00% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
18
|
¥4.07k | Buy/Sell | ¥0.00 | 35.30% |
AbbVie Net Income Forecast for 2023 - 2025 - 2030
In the last three years, AbbVie's Net Income has grown, increasing from $7.88B to $11.85B – a growth of 50.28%. The next year looks promising for AbbVie, with analysts predicting Net Income of $21.29B – an increase of 79.75%. Over the next eight years, experts anticipate that AbbVie's Net Income will grow at a rate of 101.32%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BIIB Stock Forecast | Biogen Inc | Outperform |
11
|
$255.02 | Buy/Sell | $322.44 | 27.44% |
| 4519 Stock Forecast | Chugai Pharmaceutical | Hold |
18
|
¥3.31k | Buy/Sell | ¥0.00 | 36.03% |
| ALC Stock Forecast | Alcon | Outperform |
15
|
CHF66.18 | Buy/Sell | CHF0.00 | 30.51% |
AbbVie EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, AbbVie's EBITDA has grown from $16.26B to $19.66B – a 20.87% increase. Next year, analysts are expecting EBITDA to reach $27.70B – an increase of 40.89%. Over the next eight years, the forecast is for EBITDA to grow by 61.50%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GMAB Stock Forecast | Genmab A/S | Outperform |
16
|
kr3.00k | Buy/Sell | kr2.84k | -8.24% |
| BEI Stock Forecast | Beiersdorf | Outperform |
17
|
124.05€ | Buy/Sell | 110.36€ | -7.30% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$37.50 | Buy/Sell | $60.73 | 54.67% |
AbbVie EBIT Forecast for 2023 - 2025 - 2030
In the last two years, AbbVie's EBIT has grown by 37.07%, rising from $14.25B to $19.53B. For next year, analysts predict EBIT of $26.78B, which would mean an increase of 37.11%. Over the next eight years, experts predict that AbbVie's EBIT will grow at a rate of 60.72%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| HZNP Stock Forecast | Horizon Therapeutics Public | Buy |
16
|
$113.00 | Buy/Sell | $0.00 | 23.89% |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.92k | Buy/Sell | ¥0.00 | 24.74% |
| BMRN Stock Forecast | BioMarin Pharmaceutical Inc | Outperform |
10
|
$87.04 | Buy/Sell | $115.45 | 37.87% |
AbbVie EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, AbbVie's EPS has seen a drop from $8.94 to $6.69 – a 25.17% decrease. For next year, the 23 analysts predict EPS of $12.01, which would mean an increase of 79.52%. Over the next eight years, the pros' prediction is EPSof $14.32, which would mean a eight-year growth forecast of 114.05%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4452 Stock Forecast | Kao | Outperform |
18
|
¥5.11k | Buy/Sell | ¥0.00 | 17.53% |
| 4523 Stock Forecast | Eisai | Hold |
18
|
¥8.15k | Buy/Sell | ¥0.00 | -18.99% |
| INCY Stock Forecast | Incyte Corp | Outperform |
9
|
$58.75 | Buy/Sell | $88.18 | 46.38% |
.jpg)